| Product Unit Size | Cost | Quantity | Stock |
|---|
AVL-292 is a Bruton’s tyrosine kinase (BTK) inhibitor that exhibits anticancer chemotherapeutic activities. AVL-292 is in clinical development as a potential treatment for B-cell-related disorders such as chronic lymphocytic leukemia (CLL).
| Cas No. | 1202757-89-8 |
|---|---|
| Purity | ≥98% |
| Formula | C22H22FN5O3 |
| Formula Wt. | 423.44 |
| Chemical Name | N-[3-[[5-fluoro-2-[4-(2-methoxyethoxy)anilino]pyrimidin-4-yl]amino]phenyl]prop-2-enamide |
| IUPAC Name | N-[3-[[5-fluoro-2-[4-(2-methoxyethoxy)anilino]pyrimidin-4-yl]amino]phenyl]prop-2-enamide |
| Synonym | CC-292; spebrutinib; AVL292 |
| Solubility | DMSO 85 mg/mL (200.73 mM) Water Insoluble Ethanol Insoluble |
| Appearance | White to off white powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Burger JA. Bruton's tyrosine kinase (BTK) inhibitors in clinical trials. Curr Hematol Malig Rep. 2014 Mar;9(1):44-9. PMID: 24357428.
Robak T, Robak E. Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders. Expert Opin Investig Drugs. 2012 Jul;21(7):921-47. PMID: 22612424.